Deucravacitinib in Adults with Psoriatic Arthritis
Positive Topline Results from Two Pivotal Phase 3 Trials
Recently results from POETYK PsA-1 (IM011-054) and POETYK PsA-2 (IM011-055), the pivotal Phase 3 trials evaluating the efficacy and safety of Deucravacitinib in adults with active psoriatic arthritis (PsA), were announced. Both trials met their primary endpoint, with a significantly greater proportion of Deucravacitinib-treated patients achieving ACR20 response (at least a 20 percent improvement in signs and symptoms of disease) after 16 weeks of treatment compared with placebo.
